Rigel(US:RIGL)2025-05-06 20:30Financial Performance - Q1 2025 net product sales grew to $43.6 million, a 68% increase compared to Q1 2024[18, 92] - TAVALISSE net product sales in Q1 2025 were $28.5 million, a 35% increase compared to Q1 2024[20] - GAVRETO net product sales in Q1 2025 were $9.0 million[22] - REZLIDHIA net product sales in Q1 2025 were $6.1 million[22] - Collaboration revenues for Q1 2025 totaled $9.8 million[92] - Rigel anticipates 2025 total revenue of approximately $200 million to $210 million[96] - The company projects net product sales of approximately $185 million to $192 million for 2025, representing a 28% to 32% year-over-year growth[97, 98] Clinical Development Programs - Rigel is evaluating R289, a dual IRAK1/4 inhibitor, in a Phase 1b study for relapsed/refractory lower-risk MDS[13] - The company plans to initiate a Phase 2 study of olutasidenib in recurrent glioma[13] - Preliminary data from the R289 Phase 1b study in relapsed/refractory lower-risk MDS showed that at 500 & 750 mg QD doses, RBC-TI/HI-E responses occurred in 40% of evaluable TD patients[59] Strategic Initiatives - Rigel is focused on identifying and in-licensing new late-stage assets that leverage current capabilities and capacity[10] - The company expanded its relationship with Kissei to include REZLIDHIA in Japan, the Republic of Korea, and Taiwan and entered into a relationship with Dr Reddy's in Latin America and other territories[29]